ERBB2 and triple-negative breast carcinoma: Unlike many previously established PDO protocols, which primarily utilize Matrigel and focus on morphological fidelity or a single subtype, our method allows for the efficient isolation and maintenance of PDOs from multiple clinically relevant breast cancer subtypes, such as luminal, HER2-enriched, and triple-negative breast cancers in basement membrane matrix hydrogel.